Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Cabaletta Bio Inc CABA

Healthcare Biotechnology
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome... see more

Current News (NDAQ:CABA)

Cabaletta Bio Announces 2026 Strategic Priorities

GlobeNewswire 6 days ago

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 10, 2025

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

GlobeNewswire November 4, 2025

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

GlobeNewswire October 27, 2025

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

GlobeNewswire October 14, 2025

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

GlobeNewswire October 9, 2025

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

GlobeNewswire August 27, 2025

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 7, 2025

Cabaletta Bio Announces Pricing of Public Offering of Securities

GlobeNewswire June 11, 2025
View More News ››

Opinion & Analysis (NDAQ:CABA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CABA)

Buy buddy buy because it's taking off this morning.

This stock is signalling a big upswing for shareholders today and
coolfooldumbguy - May 16, 2025

RE:RE:Looks interesting

Have played it a few times over the past few yrs. I think they are on their way this yr.
Menger - May 15, 2025

RE:Looks interesting

A really nice run here.  Took some profit out though
mevani - August 3, 2020

Looks interesting

Took a starter postion here on the dip.   I have a feeling this will find its way back up soon. 
mevani - May 15, 2020
View more Bullboard ››

Kobrea Exploration Corp.

Kobrea Exploration Corp.

Kobrea Exploration Corp. engages in the acquisition, exploration, and evaluation of mineral properties in Canada. It holds a ...
View More »

Podcasts